bdcA

biofilm dispersal protein

Overview

Drug Classes: nalidixic acid|norfloxacin|ciprofloxacin|levofloxacin, norfloxacin
Organisms: E. coli, Escherichia coli
Papers: 2
Mutations: 1

Mutations

Protein Change	Nucleotide Change	Mechanism	Organism	Resistance To	Database	Validation Status
G135S	-	-	E. coli, Escherichia coli	nalidixic acid\|norfloxacin\|ciprofloxacin\|levofloxacinnorfloxacin	Reslit	Candidate

Papers2

Mutations in bdcA and valS Correlate with Quinolone Resistance in Wastewater Escherichia coli.

novel nonsynonymous mutation

Protein Change: G135S
Organisms: E. coli
Confers Resistance To: nalidixic acid|norfloxacin|ciprofloxacin|levofloxacin
Validation Method: genome-wide association study (GWAS)
Source Database: Reslit

Word-based GWAS harnesses the rich potential of genomic data for E. coli quinolone resistance.